Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to -$2.2 million.

  • OptimizeRx's Change in Accured Expenses fell 93333.33% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 21729.55%. This contributed to the annual value of $1.1 million for FY2024, which is 1918.65% down from last year.
  • OptimizeRx's Change in Accured Expenses amounted to -$2.2 million in Q3 2025, which was down 93333.33% from $3.3 million recorded in Q2 2025.
  • OptimizeRx's Change in Accured Expenses' 5-year high stood at $3.3 million during Q2 2025, with a 5-year trough of -$2.2 million in Q3 2025.
  • Over the past 5 years, OptimizeRx's median Change in Accured Expenses value was $267000.0 (recorded in 2024), while the average stood at $234216.3.
  • In the last 5 years, OptimizeRx's Change in Accured Expenses skyrocketed by 601064.61% in 2023 and then tumbled by 93333.33% in 2025.
  • OptimizeRx's Change in Accured Expenses (Quarter) stood at $536185.0 in 2021, then surged by 74.63% to $936323.0 in 2022, then fell by 15.2% to $794000.0 in 2023, then surged by 284.13% to $3.0 million in 2024, then tumbled by 172.95% to -$2.2 million in 2025.
  • Its Change in Accured Expenses was -$2.2 million in Q3 2025, compared to $3.3 million in Q2 2025 and $854000.0 in Q1 2025.